| Style | Citing Format |
|---|---|
| MLA | Sanaye Pasand M R, et al.. "Immunomodulatory Effects of Glycyrrhizin and Glucomannan on Cytokine Gene Expression in Human Pbmcs: Implications for Vaccine Adjuvant Development." DARU, Journal of Pharmaceutical Sciences, vol. 34, no. 2, 2026, pp. -. |
| APA | Sanaye Pasand M R, Shamsnia H S, Shahverdi A R, Delnavazi M R, Yazdi M H (2026). Immunomodulatory Effects of Glycyrrhizin and Glucomannan on Cytokine Gene Expression in Human Pbmcs: Implications for Vaccine Adjuvant Development. DARU, Journal of Pharmaceutical Sciences, 34(2), -. |
| Chicago | Sanaye Pasand M R, Shamsnia H S, Shahverdi A R, Delnavazi M R, Yazdi M H. "Immunomodulatory Effects of Glycyrrhizin and Glucomannan on Cytokine Gene Expression in Human Pbmcs: Implications for Vaccine Adjuvant Development." DARU, Journal of Pharmaceutical Sciences 34, no. 2 (2026): -. |
| Harvard | Sanaye Pasand M R et al. (2026) 'Immunomodulatory Effects of Glycyrrhizin and Glucomannan on Cytokine Gene Expression in Human Pbmcs: Implications for Vaccine Adjuvant Development', DARU, Journal of Pharmaceutical Sciences, 34(2), pp. -. |
| Vancouver | Sanaye Pasand M R, Shamsnia H S, Shahverdi A R, Delnavazi M R, Yazdi M H. Immunomodulatory Effects of Glycyrrhizin and Glucomannan on Cytokine Gene Expression in Human Pbmcs: Implications for Vaccine Adjuvant Development. DARU, Journal of Pharmaceutical Sciences. 2026;34(2):-. |
| BibTex | @article{ author = {Sanaye Pasand M R and Shamsnia H S and Shahverdi A R and Delnavazi M R and Yazdi M H}, title = {Immunomodulatory Effects of Glycyrrhizin and Glucomannan on Cytokine Gene Expression in Human Pbmcs: Implications for Vaccine Adjuvant Development}, journal = {DARU, Journal of Pharmaceutical Sciences}, volume = {34}, number = {2}, pages = {-}, year = {2026} } |
| RIS | TY - JOUR AU - Sanaye Pasand M R AU - Shamsnia H S AU - Shahverdi A R AU - Delnavazi M R AU - Yazdi M H TI - Immunomodulatory Effects of Glycyrrhizin and Glucomannan on Cytokine Gene Expression in Human Pbmcs: Implications for Vaccine Adjuvant Development JO - DARU, Journal of Pharmaceutical Sciences VL - 34 IS - 2 SP - EP - PY - 2026 ER - |